NCT01407848.

Trial name or title	Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea
Methods	Estimated enrolment: 20 Randomised, double‐blind trial Parallel assignment Inclusion criteria: Neonates with 35 + 0 − 39 + 0 GA on the first day of life with the clinical diagnosis of transient tachypnoea; the need for CPAP > 6 h to obtain the oxygen saturation > 92%; written informed consent of parent/guardian Exclusion Criteria: Systemic infection; intubation and mechanical ventilation before Inclusion in the trial; malformation and any other of several diseases with respiratory disturbance; participants involved in other clinical trials
Participants	Preterm and term neonates with transient tachypnoea
Interventions	Patients received nebulised Furosemide IV solution 1 mg/kg (4x/d) for max. 3 consecutive days versus nebulised 0.9% saline 4x/d for max. 3 days
Outcomes	Primary outcome: Reduction of the Silverman score Secondary outcome: Oxygen supplementation, a need for secondary intubation and mechanical ventilation, body weight, CPAP‐time, blood electrolytes, and blood gas
Starting date	January 2012
Contact information	Prof. Bernhard Roth Children's Hospital University of Cologne Cologne, NRW, Germany, 50931 +49221478 ext 5064 bernd.roth@uk‐koeln.de
Notes	NCT01407848

CPAP: continuous positive airway pressure
 GA: gestational age
 h: hour(s)